Trial Profile
Multicenter prospective trial after first unsuccesful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistance of molecular remission after stopping tyrosine kinase inhibitors a second time or 3rd time
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NAUT
- 04 Nov 2021 Planned End Date changed from 1 Sep 2026 to 1 Sep 2027.
- 04 Nov 2021 Planned primary completion date changed from 1 Sep 2025 to 1 Sep 2026.
- 04 Nov 2021 Status changed from recruiting to active, no longer recruiting.